Published in Clin Cancer Res on February 01, 2008
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol (2009) 1.28
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol (2009) 1.26
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer (2010) 1.22
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci (2014) 1.16
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol (2011) 1.10
Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One (2011) 1.09
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer (2010) 1.05
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer (2013) 1.03
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol (2010) 1.03
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol (2009) 1.01
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res (2014) 0.98
Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol (2012) 0.98
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer (2010) 0.98
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer (2009) 0.97
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle (2011) 0.95
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Epigenomics and ovarian carcinoma. Biomark Med (2010) 0.91
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers (Basel) (2013) 0.89
Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res (2013) 0.89
Targeted therapy for advanced thymic tumors. J Thorac Oncol (2010) 0.87
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer (2011) 0.87
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One (2013) 0.86
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol (2011) 0.86
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Cancer Med (2015) 0.85
Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res (2011) 0.85
Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel) (2010) 0.85
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol (2013) 0.83
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol (2011) 0.81
Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol (2012) 0.81
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy (2015) 0.81
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine (2013) 0.81
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs (2014) 0.80
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets Ther (2014) 0.79
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol (2013) 0.79
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther (2012) 0.79
Potential use of histone deacetylase inhibitors in cancer therapy. Contemp Oncol (Pozn) (2015) 0.77
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma (2016) 0.76
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors. Onco Targets Ther (2012) 0.76
Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Front Pharmacol (2015) 0.75
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. J Adv Pract Oncol (2016) 0.75
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist (2015) 0.75
Drug monographs: belinostat and idelalisib. Hosp Pharm (2014) 0.75
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol (2015) 0.75
The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death. Sci Rep (2015) 0.75
New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res (2015) 0.75
Quinazoline derivative QPB-15e stabilizes the c-myc promoter G-quadruplex and inhibits tumor growth in vivo. Oncotarget (2016) 0.75
A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas. Sarcoma (2016) 0.75
Belinostat exerts anti-tumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma. Mol Oncol (2017) 0.75
Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies. Invest New Drugs (2016) 0.75
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood (2009) 2.28
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2010) 1.81
Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis (2005) 1.77
CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol (2008) 1.72
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther (2006) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res (2009) 1.63
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 1.57
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer (2007) 1.51
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc (2010) 1.47
LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology (2010) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med (2012) 1.46
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Recommendations for improved acute pain services: Canadian collaborative acute pain initiative. Pain Res Manag (2004) 1.33
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol (2012) 1.33
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res (2008) 1.33
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat (2004) 1.32
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28
DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology (2013) 1.28
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol (2010) 1.23
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Spirometry testing standards in spinal cord injury. Chest (2003) 1.22
Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. Proc Natl Acad Sci U S A (2012) 1.22
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15
The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res (2004) 1.15
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. Stroke (2008) 1.10
Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil (2006) 1.09
Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology (2008) 1.07
Microcalorimetric study of ammonia chemisorption on H3PW12O40 supported onto mesoporous synthetic carbons and SBA-15. Langmuir (2006) 1.05
Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol (2005) 1.04
Clinical ventilator adjustments that improve speech. Chest (2003) 1.04
Growth of Rhodospirillum rubrum on synthesis gas: conversion of CO to H2 and poly-beta-hydroxyalkanoate. Biotechnol Bioeng (2007) 1.04
Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg (2005) 1.03
Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. Aging Cell (2010) 1.03
High-throughput gene discovery in the rat. Genome Res (2004) 1.02
Diagnostic radiation exposure in pediatric trauma patients. J Trauma (2011) 1.02
Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology (2013) 1.02
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer (2006) 1.00
On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J Med Chem (2013) 0.99
Dyspnea during daily activities in chronic spinal cord injury. Arch Phys Med Rehabil (2005) 0.99
Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale. J R Soc Interface (2010) 0.99
Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Cancer Res (2013) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites. Chemistry (2011) 0.98
Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther (2004) 0.98